104 trexate and Tacrolimus (Prograf, FK506) With Methotrexate and Cyclosporine for Graft-Versus-Host disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation. Blood 1998;92(7):2303-2314. [34] Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21:389.e1-401.e1 [35] Newell LF, Holtan SG. Acute GVGD: think before you treat. Hematology Am Soc Hematol Educ Program 2021;1:642-647 [36] Zeiser R, Blazar BR. Acute Graft-versus-Host Disease- Biologic Process, Prevention, and Therapy. N Eng J Med. 2017;377:2167-2179 [37] Vo P, Gooley TA, Carpenter PA, Sorror ML, MacMillan ML, DeFor TE, et al. Prediction of outcomes after second-line treatment for acute graft-versus-host disease. Blood Adv 2022;6(11):32203229 [38] Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2021;18(8):1150-1163 [39] Martin PJ. How I treat steroid-refractory acute graft-versushost disease. Blood 2020;135(19):1630-1638 [40] Malard F, Huang XJ, Sim JPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia 2020;34(5):1229-1240 [41] Toubai T, Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease. Blood 2020;136(4):429-440 [42] Zeiser R, Burchert A, Lengerke C, Verbeek M, Mass-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graftversus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015;29:2062-2068 [43] Kharfan-Dabaja MA, Kumar A, Ayala E, Alijurf M, Nishihori T, Marsh R, et al. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transpl Cell Therapy 2021;27(8):642-649 [44] Olsson R, Remberger M, Schaffer DM, Berggren DM, Svahn BM, Mattsson J, et al. Graft failure in the modern era of allogeneic SCT. Bone Marrow Transplant. 2013;48:537-543 [45] Peci F, Dekker L, Pagliaro A, van Boxtel R, Nierkens S, Belderbos M. The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2022. https://doi.org/10.1038/s41409-02201728-0 [46] Kong Y, Chang YJ, Wang YZ, Chen YH, Han W, Wang Y, et al. Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19(10):1465-1473 [47] Zhao Y, Gao F, Shi J, Luo Y, Tan Y, Lai X, et al. Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019;25(9):1898-1907 [48] Mattsson J, Ringden O, Storb R. Graft Failure after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2008;14(1):165-170 [49] Ferrá C, Sanz J, Díaz-Pérez M-A, Morgades M, Gayoso J, Cabrera J-R, et al. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leukemia & Lymphoma. 2014;56(3):656–662.
RkJQdWJsaXNoZXIy ODUzNzk5